RPG Life Sciences Ratios

RPG Life Sciences Ltd Ratios

The RPG Life Sciences Ltd Ratios page provides a complete fundamental analysis of RPG Life Sciences Ltd using key valuation, profitability, and financial strength metrics. Investors tracking RPG Life Sciences Ltd Ratios closely monitor D/E, EV, EV/EBITDA, P/B, P/CF, P/E, P/S, and ROE% to evaluate the company's financial performance and valuation trends over time.

RPG Life Sciences Ltd (NSE: RPGLIFE, BSE: 532983) is currently trading at ₹1881, with a market capitalization of ₹31.08B. As a major player in the Health technology sector and Pharmaceuticals: major industry, RPG Life Sciences Ltd remains a key stock for fundamental analysis using RPG Life Sciences Ltd Ratios.

RPG Life Sciences Ltd Ratios: Valuation Overview

Price to Earnings Ratio (P/E)

The RPG Life Sciences Ltd P/E ratio currently stands at 20.56, making it one of the most tracked metrics in RPG Life Sciences Ltd Ratios.

Historically, the RPG Life Sciences Ltd P/E ratio has shown strong fluctuations:

• 2024: 20.56
• 2023: 28.87
• 2022: 17.02
• 2021: 17.98
• 2020: 16.01

The decline in RPG Life Sciences Ltd P/E ratio suggests improving earnings relative to stock price.

Price to Book Ratio (P/B)

The RPG Life Sciences Ltd P/B ratio reflects how the market values the company's net assets. Current P/B ratio is 7.10.

Historical P/B trend:

• 2024: 7.10
• 2023: 6.75
• 2022: 3.74
• 2021: 3.62

RPG Life Sciences Ltd is trading at a premium to its book value, indicating strong market confidence.

Price to Sales Ratio (P/S)

The RPG Life Sciences Ltd P/S ratio currently stands at 5.80, an important part of RPG Life Sciences Ltd Ratios for revenue valuation.

Historical P/S ratio:

• 2024: 5.80
• 2023: 4.37
• 2022: 2.26
• 2021: 2.11

The rising RPG Life Sciences Ltd P/S ratio indicates improved revenue valuation by investors.

RPG Life Sciences Ltd Price to Cash Flow Ratio (P/CF)

The RPG Life Sciences Ltd Price to Cash Flow Ratio is a key valuation metric that shows how much investors pay for each unit of cash flow. Current P/CF ratio is 46.82.

Historical RPG Life Sciences Ltd Price to Cash Flow Ratio:

• 2024: 46.82
• 2023: 26.55
• 2022: 12.34
• 2021: 14.09
• 2020: 11.03

The rising RPG Life Sciences Ltd Price to Cash Flow Ratio indicates premium valuation based on cash flow.

RPG Life Sciences Ltd Enterprise Value Ratios

Enterprise Value (EV)

The RPG Life Sciences Ltd EV currently stands at ₹35.01B, representing the total company valuation including debt.

Historical EV trend:

• 2024: 35.01B
• 2023: 24.04B
• 2022: 10.35B
• 2021: 8.56B

RPG Life Sciences Ltd enterprise value shows long-term growth, reflecting expansion and market confidence.

EV/EBITDA Ratio

The RPG Life Sciences Ltd EV/EBITDA ratio is currently 21.87, a key metric in RPG Life Sciences Ltd Ratios to assess valuation relative to earnings.

Historical EV/EBITDA:

• 2024: 21.87
• 2023: 18.92
• 2022: 10.06
• 2021: 9.94

Higher RPG Life Sciences Ltd EV/EBITDA suggests premium valuation.

RPG Life Sciences Ltd Financial Strength Ratios

Debt to Equity Ratio (D/E)

The RPG Life Sciences Ltd D/E ratio is currently 0, reflecting leverage and financial stability.

Historical D/E:

• 2024: 0
• 2023: 0
• 2022: 0
• 2021: 0

RPG Life Sciences Ltd maintains a strong balance sheet with low debt levels.

Return on Equity (ROE %)

The RPG Life Sciences Ltd ROE currently stands at 40.48%, showing profitability and capital efficiency.

Historical ROE:

• 2024: 40.48
• 2023: 25.69
• 2022: 24.01
• 2021: 21.80

RPG Life Sciences Ltd demonstrates strong profitability and efficient capital utilization.

RPG Life Sciences Ltd Ratios Analysis Summary

The RPG Life Sciences Ltd Ratios page provides a comprehensive view of the company's valuation and financial performance. Key metrics such as P/E, P/B, P/S, P/CF, EV, EV/EBITDA, D/E, and ROE help investors understand whether RPG Life Sciences Ltd stock is undervalued, fairly valued, or overvalued.

Tracking RPG Life Sciences Ltd Ratios regularly helps investors make informed decisions based on valuation trends, financial stability, and long-term growth potential.